Ask AI
ProCE Banner Activity

Clinical Integration of ADCs Into Treatment Plans for Patients With NSCLC: Answers to Your Questions

Clinical Thought

Gain expert insights on key questions for optimizing ADC therapy for NSCLC, with clinically relevant guidance on managing interstitial lung disease and ADC treatment-related adverse events.

Released: September 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Matthew Gubens, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Atreca, Bicycle, Bristol Myers Squibb, Cardinal Health, Catalyst, Genentech, Invitae, Johnson & Johnson, Merus, Natera, Nuvalent, OncoHost, Regeneron; researcher (paid to institution): Amgen, Johnson & Johnson, Merck, Trizell.

Rebecca S. Heist, MD, MPH: consultant/advisor/speaker: Amgen, AstraZeneca, Biohaven, Claim Therapeutics, Daiichi Sankyo, Gilead, Lilly, Merck.

Ticiana Leal, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Jazz, Johnson & Johnson, Merck, Molecular Partners, Naterra, Novocure, Pfizer, Regeneron, Roche, Sanofi, Summit, Synthekine.